


**COMBAT** CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

The emergence and spread of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) are a significant clinical and public health concern. MicroScan continues to offer the most clinically relevant antibiotics and dilutions, including the introduction of Meropenem/Vaborbactam (MEV), effective in the treament of select CRE.





## Reduce costs through fewer ancillary tests

Test resistance to MEV alongside clinically relevant antibiotics:

- The latest agents with activity vs. select MDR CRE organisms
- > Extended fluoroquinolone dilutions
- 30 antibiotic tests including all 3 carbapenems and ESβL confirmation



# Expand and update antibiotic options with the new Select Series of panels

Update your offering of antibiotics with the most current and clinically relevant antibiotics and dilutions on the market.



## Advance stewardship initiatives

CRE bacteria is a growing threat in hospital care.

- Treat patients with serious infections as quickly and efficiently as possible
- Implement an ideal companion panel for MALDI ID users

Contact your local sales representative to bring this new panel to your laboratory.



### C42464 Neg MIC 56 (NM56)

| Abbr.  | Antimicrobial Agent           | Dilutions    |
|--------|-------------------------------|--------------|
| Ak     | Amikacin                      | 16-32        |
| Aug    | Amoxicillin/K Clavulanate     | 8/4-16/8     |
| Am     | Ampicillin                    | 8-16         |
| A/S    | Ampicillin/Sulbactam          | 4/2-16/8     |
| Azt    | Aztreonam                     | 4-16         |
| Cfz    | Cefazolin                     | 2-16         |
| Cpe    | Cefepime                      | 2-16         |
| Cft    | Cefotaxime                    | 2, 8-32      |
| Cft/CA | Cefotaxime/K Clavulanate      | 0.5/4, 4/4   |
| CftE   | Cefotaxime-ESbL               | 1            |
| Cfx    | Cefoxitin                     | 8-16         |
| Caz    | Ceftazidime                   | 1, 4-16      |
| CZA ★  | Ceftazidime/Avibactam         | 4/4-16/4     |
| Caz/CA | Ceftazidime/K Clavulanate     | 0.25/4, 2/4  |
| C/T ★  | Ceftolozane/Tazobactam        | 2/4-8/4      |
| Cax    | Ceftriaxone                   | 1-2, 8, 32   |
| Crm    | Cefuroxime                    | 4-16         |
| Ср     | Ciprofloxacin                 | 0.25-2       |
| Etp    | Ertapenem                     | 0.5-1        |
| Gm     | Gentamicin                    | 2-8          |
| Imp    | Imipenem                      | 1–8          |
| Lvx    | Levofloxacin                  | 0.5-4        |
| Mer    | Meropenem                     | 1–8          |
| MEV ★  | Meropenem/Vaborbactam         | 2/8-16/8     |
| Min    | Minocycline                   | 4-8          |
| Mxf    | Moxifloxacin                  | 2-4          |
| Fd     | Nitrofurantoin                | 32-64        |
| P/T    | Piperacillin/Tazobactam       | 8/4-64/4     |
| Te     | Tetracycline                  | 4-8          |
| Tgc    | Tigecycline                   | 2-4          |
| То     | Tobramycin                    | 2-8          |
| T/S    | Trimethoprim/Sulfamethoxazole | 0.5/9.5-2/38 |

#### **Select Series**

## C42464, Neg MIC 56 Panel includes:

- > The latest agents with activity vs. MDR CRE organisms ★
  - Ceftazidime/Avibactam
  - Ceftolozane/Tazobactam
  - Meropenem/Vaborbactam
- > Extended fluoroquinolone dilutions to support Enterobacteriaceae and P. aeruginosa breakpoints
- ➤ Minocycline for an alternative to MDR Enterobacteriaceae and Acinetobacter ◆
- > All three carbapenems
- 30 antibiotic tests including all three carbapenems and ESBL confirmation

See how Beckman Coulter microbiology solutions are helping clinical laboratories in the fight against antibiotic resistance.

www.beckmancoulter.com/en/products/microbiology/conventional-panels

